€23.96
0.25% today
Xetra, Dec 18, 05:35 pm CET
ISIN
DE000A3ENQ51
Symbol
1SXP
Index
Sector
Industry

SCHOTT Pharma Target price 2024 - Analyst rating & recommendation

SCHOTT Pharma Classifications & Recommendation:

Buy
40%
Hold
60%

SCHOTT Pharma Price Target

Target Price €32.74
Price €23.96
Potential
Number of Estimates 10
10 Analysts have issued a price target SCHOTT Pharma 2025 . The average SCHOTT Pharma target price is €32.74. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 10 analysts: 4 Analysts recommend SCHOTT Pharma to buy, 6 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the SCHOTT Pharma stock has an average upside potential 2025 of . Most analysts recommend the SCHOTT Pharma stock at Hold.

Sales and Margin forecast 2025, 2026 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Sep '24 2025
Estimates
Revenue Million € 957.09 1,035.14
6.46% 8.15%
EBITDA Margin 24.66% 27.34%
4.95% 10.89%
Net Margin 15.58% 15.07%
7.93% 3.27%

9 Analysts have issued a sales forecast SCHOTT Pharma 2025 . The average SCHOTT Pharma sales estimate is

€1.0b
Unlock
. This is
8.15% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
€1.1b 12.16%
Unlock
, the lowest is
€1.0b 5.63%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 €957m 6.46%
2025
€1.0b 8.15%
Unlock
2026
€1.2b 13.40%
Unlock
2027
€1.3b 11.55%
Unlock
2028
€1.4b 7.61%
Unlock

9 Analysts have issued an SCHOTT Pharma EBITDA forecast 2025. The average SCHOTT Pharma EBITDA estimate is

€283m
Unlock
. This is
18.75% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
€297m 24.52%
Unlock
, the lowest is
€263m 10.38%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 €236m 11.73%
2025
€283m 19.94%
Unlock
2026
€343m 21.35%
Unlock
2027
€396m 15.40%
Unlock
2028
€433m 9.34%
Unlock

EBITDA Margin

2024 24.66% 4.95%
2025
27.34% 10.89%
Unlock
2026
29.26% 7.02%
Unlock
2027
30.27% 3.45%
Unlock
2028
30.76% 1.62%
Unlock

7 SCHOTT Pharma Analysts have issued a net profit forecast 2025. The average SCHOTT Pharma net profit estimate is

€156m
Unlock
. This is
4.59% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
€163m 9.09%
Unlock
, the lowest is
€137m 8.01%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 €149m 1.98%
2025
€156m 4.59%
Unlock
2026
€196m 25.39%
Unlock
2027
€231m 18.26%
Unlock
2028
€267m 15.51%
Unlock

Net Margin

2024 15.58% 7.93%
2025
15.07% 3.27%
Unlock
2026
16.66% 10.55%
Unlock
2027
17.66% 6.00%
Unlock
2028
18.96% 7.36%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2028

Create a premium account to unlock analyst estimates. Learn more

Sep '24 2025
Estimates
Earnings Per Share 0.99 1.04
1.98% 5.05%
P/E 23.08
EV/Sales 3.54

7 Analysts have issued a SCHOTT Pharma forecast for earnings per share. The average SCHOTT Pharma <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

€1.04
Unlock
. This is
5.05% higher
Unlock
than earnings per share in the financial year 2024. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
€1.08 9.09%
Unlock
, the lowest is
€0.91 8.08%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 €0.99 1.98%
2025
€1.04 5.05%
Unlock
2026
€1.30 25.00%
Unlock
2027
€1.54 18.46%
Unlock
2028
€1.77 14.94%
Unlock

P/E ratio

Current
2025
23.08 4.03%
Unlock
2026
18.41 20.23%
Unlock
2027
15.56 15.48%
Unlock
2028
13.48 13.37%
Unlock

Based on analysts' sales estimates for 2025, the SCHOTT Pharma stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 3.83
2025
3.54 7.66%
Unlock
2026
3.12 11.82%
Unlock
2027
2.80 10.35%
Unlock
2028
2.60 7.07%
Unlock

P/S ratio

Current
2025
3.48 7.54%
Unlock
2026
3.07 11.82%
Unlock
2027
2.75 10.35%
Unlock
2028
2.55 7.07%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today